 |
|
|
|
|
Current
Trials
Validated Technology
Argos’ Arcelis personalized RNA-loaded dendritic cell immunotherapy technology platform has been validated
in human clinical trials in kidney cancer and HIV. In the initial clinical trials in kidney cancer, the immunotherapy
was well tolerated, induced a potent anti-tumor response and demonstrated
encouraging clinical responses. In the initial HIV clinical trial, the immunotherapy was also well tolerated and the primary endpoint of induction of T cell response to patient-specific HIV antigens was achieved. See publication section.
Therapeutic Areas
Metastatic Renal Cell Carcinoma (RCC)
Argos
is currently conducting two phase 2 clinical trials of its Arcelis immunotherapy in RCC, testing the therapy as both a single-agent and also in combination with sunitinib. Argos has completed an initial Phase 1/2 study of the immunotherapy in RCC. The trial successfully demonstrated
that the immunotherapy was well-tolerated (no drug related serious adverse
events) and the commercial feasibility of processing the product at a
central manufacturing facility with delivery to multiple clinical sites.
In addition, disease progression and overall median survival data from
the trial were encouraging.
For further information and eligibility criteria, refer
to the National Institutes of Health ClinicalTrials.gov Web site at http://www.clinicaltrials.gov/ct2/show/NCT00678119?term=argos&rank=2
Human Immunodeficiency Virus (HIV)
Argos is currently conducting a randomized, double-blind, placebo-controlled Phase 2b trial of its Arcelis immunotherapy targeted to HIV. This trial is measuring the safety and efficacy, in terms of viral load control, of the therapy. Argos recently completed treating HIV patients in a multicenter Phase 2a trial. Interim results from this Phase 2a trial, presented at the
2010 International AIDS conference, demonstrated that the candidate AGS-004 achieved a significant reduction in viral load and a delay in viral rebound kinetics during a 12-week antiretroviral treatment (ART) interruption when compared to pre-ART viral loads. The novel Argos RNA-loaded DC therapy for HIV utilizes small
plasma samples from infected patients to amplify large quantities of
viral RNA encoding selected antigens, resulting in a personalized treatment
to the patient’s own strain of virus. For further information see the following site at http://www.clinicaltrials.gov/ct2/show/NCT01069809?term=ARgos+and+HIV&rank=3
Systemic Lupus Erythematosus (SLE)
Argos has an anti-Interferon-alpha monoclonal antibody, AGS-009, that is being tested in a phase 1 clinical trial in SLE patients.
http://www.clinicaltrials.gov/ct2/show/NCT00960362?term=ARgos+and+SLE&rank=1 CLINICAL PIPELINE
| Description |
Indication |
Status |
| AGS-003 |
Metastatic Renal Cell Carcinoma |
Ph 2 |
| AGS-004 |
HIV |
Ph 2 |
| AGS-009 |
Lupus |
Ph 1 |
|
|
|
 |
|
